IL17A and psoriasis: In addition, STAT1-57 genes were repressed in psoriasis lesions following treatment of patients with biologic agents, including anti-TNF therapy (P = 2.1×10−8; GSEA; Figure S14A), anti-IL-17A therapy (P = 9.9×10−8; GSEA; Figure S14B) and efalizumab (P = 4.5×10−12; GSEA; Figure S14C).